肉瘤治疗的新途径及分子靶点研究进展  

Research progress on novel pathways and molecular targets for the treatment of sarcoma

作　　者：贾志峰[1] 赵亚恒[2] 史晓熠 冯建刚[1] 

机构地区：[1]河北医科大学第四医院骨科,石家庄050017 [2]河北医科大学研究生院,石家庄050017

出　　处：《国际外科学杂志》2014年第5期345-348,共4页International Journal of Surgery

摘　　要：骨与软组织肉瘤亚型约100多种,它们对化疗多不敏感,这就需要研发组织特异性或通路特异性疗法.随着我们对肉瘤发病分子机制的深入理解,一系列的靶向疗法应运而生.最近发现的新药物靶点有：在高分化或去分化脂肪肉瘤中MDM2扩增,孤立性纤维瘤中NAB2：STAT6基因融合,胃肠道间质瘤中SDH突变,滑膜肉瘤中Mcl1抑制,小泡型横纹肌肉瘤中CDK4激活等.它们将在肉瘤治疗中发挥重要作用,本文就此进行综述.Sarcomas collectively represent over 100 different subtypes of bone and soft tissue tumors.They are not sensitive to chemotherapy,which requires the development of tissue-specific or pathway-specific therapies.As our understanding of the molecular mechanisms driving sarcomas is rapidly advancing,the number of targeted therapies is also increasing.Recently identified novel druggable targets including the MDM2 amplifications in welldifferentiated and dedifferentiated liposarcomas,the fusion NAB2：STAT6 of solitary fibrous tumor,the SDH mutations in gastrointestinal stro mal tumors,the suppression of Mcl1 in synovial sarcomas,CDK4 in alveolar rhabdomyosarcoma.They will play an important role in the treatment of sarcoma.Here,the author do an overview of these factors.

关 键 词：肉瘤 治疗结果 分子靶点 综述 

分 类 号：R730.5[医药卫生—肿瘤]